Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20030172 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL22022994 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL22814028 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL15616007 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL20030173 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL20030175 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL12179827 | 0.96 | FAAH (0.50) | EPHX2FAAHTRPV1LPAR1LPAR2 | |
| SCHEMBL12179809 | 0.96 | FAAH (0.50) | EPHX2FAAHTRPV1LPAR1LPAR2 | |
| SCHEMBL20017981 | 0.96 | FAAH (0.50) | EPHX2FAAHTRPV1LPAR1LPAR2 | |
| SCHEMBL12179849 | 0.96 | FAAH (0.50) | EPHX2FAAHTRPV1LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | KYOWA KIRIN CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3662913-A1 | NUCLEIC-ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Kirin Co., Ltd. (JP) | 2020-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | LIPA, LIPC, PNLIP | EPHX2 1410/4885FAAH 89/4885TRPV1 3502/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | EPHX2 1410/4885FAAH 89/4885TRPV1 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.